Ibrance-话题@MedSci - 梅斯（MedSci）

#Ibrance#

10篇内容 | 1226人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1443910, encodeId=42a6144391055, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=Ibrance联合标准疗法治疗乳腺癌：未达到主要终点, objectType=article, longId=195119, objectId=4c951951194a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c951951194a, replyNumber=0, likeNumber=64, createdTime=2020-06-03, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c951951194a, moduleTitle=Ibrance联合标准疗法治疗乳腺癌：未达到主要终点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4c951951194a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443909, encodeId=41051443909f2, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, objectType=article, longId=186505, objectId=22ce186505e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ce186505e0, replyNumber=0, likeNumber=142, createdTime=2020-01-20, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ce186505e0, moduleTitle=辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=22ce186505e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443908, encodeId=709b144390804, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, objectType=article, longId=184022, objectId=bfe4184022fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4184022fb, replyNumber=0, likeNumber=96, createdTime=2019-12-04, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4184022fb, moduleTitle=英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bfe4184022fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443907, encodeId=9d01144390e8e, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=FDA警告Ibrance、Kisqali和Verzenio治疗乳腺癌，可能会引起罕见但严重的肺部炎症, objectType=article, longId=179490, objectId=0b901e949005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b901e949005, replyNumber=0, likeNumber=62, createdTime=2019-09-17, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b901e949005, moduleTitle=FDA警告Ibrance、Kisqali和Verzenio治疗乳腺癌，可能会引起罕见但严重的肺部炎症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0b901e949005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443906, encodeId=77941443906a8, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=FDA宣布将辉瑞的Ibrance在转移性乳腺癌中的适应症扩展至男性患者, objectType=article, longId=163910, objectId=419e163910bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=419e163910bc, replyNumber=0, likeNumber=51, createdTime=2019-04-10, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=419e163910bc, moduleTitle=FDA宣布将辉瑞的Ibrance在转移性乳腺癌中的适应症扩展至男性患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=419e163910bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443905, encodeId=e5281443905f1, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, objectType=article, longId=163717, objectId=ffde163e1796, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffde163e1796, replyNumber=0, likeNumber=49, createdTime=2019-04-07, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffde163e1796, moduleTitle=男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ffde163e1796)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443904, encodeId=e113144390431, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期, objectType=article, longId=141716, objectId=f67b141e169c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f67b141e169c, replyNumber=0, likeNumber=68, createdTime=2018-06-28, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f67b141e169c, moduleTitle=辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f67b141e169c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443903, encodeId=e15a1443903af, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=美国FDA授予辉瑞突破性乳腺癌新药Ibrance优先审查资格, objectType=article, longId=85251, objectId=9bd48525153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bd48525153, replyNumber=0, likeNumber=67, createdTime=2016-12-25, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bd48525153, moduleTitle=美国FDA授予辉瑞突破性乳腺癌新药Ibrance优先审查资格, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9bd48525153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443902, encodeId=bbc9144390207, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=ESMO ASIA 2016：辉瑞突破性乳腺癌药物Ibrance在亚洲ER+/HER2-转移性乳腺癌患者中疗效显著, objectType=article, longId=85001, objectId=ab7e85001cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab7e85001cf, replyNumber=0, likeNumber=72, createdTime=2016-12-23, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab7e85001cf, moduleTitle=ESMO ASIA 2016：辉瑞突破性乳腺癌药物Ibrance在亚洲ER+/HER2-转移性乳腺癌患者中疗效显著, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ab7e85001cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1443901, encodeId=dee1144390199, content=<a href='/topic/show?id=4fa89316ee' target=_blank style='color:#2F92EE;'>#Ibrance#</a>, objectTitle=乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功, objectType=article, longId=66979, objectId=0c7b669e992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7b669e992, replyNumber=0, likeNumber=62, createdTime=2016-04-23, rootId=0, userName=12498f6em08暂无昵称, userId=8b645125809, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7b669e992, moduleTitle=乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0c7b669e992)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Ibrance

2020-05-29

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

Ibrance联合标准疗法治疗乳腺癌：未达到主要终点

2020-06-03

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

辉瑞的CDK4/6抑制剂Ibrance，获英国NICE批准治疗乳腺癌

2020-01-20

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

英国NICE推荐将辉瑞的细胞周期蛋白依赖性激酶抑制剂Ibrance用于治疗晚期或转移性乳腺癌

2019-12-04

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

FDA警告Ibrance、Kisqali和Verzenio治疗乳腺癌，可能会引起罕见但严重的肺部炎症

2019-09-17

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

FDA宣布将辉瑞的Ibrance在转移性乳腺癌中的适应症扩展至男性患者

2019-04-10

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

男性乳腺癌：美国FDA批准IBRANCE（palbociclib）用于治疗HR+/HER2-的男性乳腺癌患者

2019-04-07

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

辉瑞的Ibrance在III期乳腺癌研究中未能显著延长生存期

2018-06-28

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

美国FDA授予辉瑞突破性乳腺癌新药Ibrance优先审查资格

2016-12-25

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

ESMO ASIA 2016：辉瑞突破性乳腺癌药物Ibrance在亚洲ER+/HER2-转移性乳腺癌患者中疗效显著

2016-12-23

12498f6em08暂无昵称 (审核中...)

前往app查看评论内容

#Ibrance#

乳腺癌新药Ibrance III期临床一线治疗ER+/HER2-乳腺癌获得成功

2016-04-23

科室
- - 订阅+
  - 更多科室
工具
服务